Key Details
Price
$6.47Annual ROE
-0.81%Beta
0.00Events Calendar
Next earnings date:
Aug 15, 2025Recent quarterly earnings:
Aug 16, 2024Recent annual earnings:
Apr 30, 2020Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Mar 20, 14 Morgan Stanley
OverweightNov 13, 13 Aegis Capital
BuyAug 15, 13 Aegis Capital
BuyMay 15, 13 Morgan Stanley
Equal-WeightMar 14, 13 Aegis Capital
HoldDec 12, 12 Aegis Capital
HoldMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Price
Market cap
Technical
Dividend
Sinovac Biotech doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Leverage
Risk & Stability
Balance Sheet
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Assets
Equity
Liabilities
Debt
Expenses
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
SVA
businesswire.comDecember 16, 2024
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet been approved for marketing worldwide. The Phase III clinical trial is designed to be a multicenter, randomized, double-blind.
FAQ
- What is the ticker symbol for Sinovac Biotech?
- Does Sinovac Biotech pay dividends?
- What sector is Sinovac Biotech in?
- What industry is Sinovac Biotech in?
- What country is Sinovac Biotech based in?
- When did Sinovac Biotech go public?
- Is Sinovac Biotech in the S&P 500?
- Is Sinovac Biotech in the NASDAQ 100?
- Is Sinovac Biotech in the Dow Jones?
- When was Sinovac Biotech's last earnings report?
- When does Sinovac Biotech report earnings?
- Should I buy Sinovac Biotech stock now?
What is the ticker symbol for Sinovac Biotech?
The ticker symbol for Sinovac Biotech is NASDAQ:SVA
Does Sinovac Biotech pay dividends?
No, Sinovac Biotech does not pay dividends
What sector is Sinovac Biotech in?
Sinovac Biotech is in the Healthcare sector
What industry is Sinovac Biotech in?
Sinovac Biotech is in the Biotechnology industry
What country is Sinovac Biotech based in?
Sinovac Biotech is headquartered in China
When did Sinovac Biotech go public?
Sinovac Biotech's initial public offering (IPO) was on September 26, 2003
Is Sinovac Biotech in the S&P 500?
No, Sinovac Biotech is not included in the S&P 500 index
Is Sinovac Biotech in the NASDAQ 100?
No, Sinovac Biotech is not included in the NASDAQ 100 index
Is Sinovac Biotech in the Dow Jones?
No, Sinovac Biotech is not included in the Dow Jones index
When was Sinovac Biotech's last earnings report?
Sinovac Biotech's most recent earnings report was on Aug 16, 2024
When does Sinovac Biotech report earnings?
The next expected earnings date for Sinovac Biotech is Aug 15, 2025
Should I buy Sinovac Biotech stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions